logo

CLYM

Climb Bio·NASDAQ
--
--(--)
--
--(--)
5.75 / 10
Netural

Fundamental analysis of CLYM is neutral (5.8/10). Strengths lie in PB-ROE (-0.3045, Group 1) and Asset-MV (-0.5007, Group 4), both historically associated with positive returns (11.47% and 14.99% one-month returns, respectively). However, challenges emerge from Net profit / Total profit (%) at 100.0% (Group 1, poor historical return -0.30%), Revenue-MV (-0.2574, Group 2, 5.20% return), and Gross profit margin (%) at 36.6994 (Group 1, negative return -0.54%). Inventory turnover (47.85, Group 2) and fixed assets turnover (7979.42, Group 3) show mixed performance, while Profit-MV (0.4634, Group 1) and Cash-MV (-0.0673, Group 1) offer moderate support. Overall, the fundamentals suggest a company with solid asset efficiency but margin and profitability concerns.

Fundamental(5.75)SentimentTechnical

Analysis Checks(7/10)

Revenue-MV
Value-0.26
Score1/3
Weight9.19%
1M Return5.20%
Inventory turnover ratio
Value47.85
Score3/3
Weight8.07%
1M Return5.26%
Gross profit margin (%)
Value36.70
Score1/3
Weight-0.71%
1M Return-0.54%
Profit-MV
Value0.46
Score2/3
Weight13.76%
1M Return7.79%
PB-ROE
Value-0.30
Score3/3
Weight21.61%
1M Return11.47%
Current assets turnover ratio
Value1.78
Score2/3
Weight1.61%
1M Return1.15%
Fixed assets turnover ratio
Value7979.42
Score3/3
Weight1.17%
1M Return0.86%
Asset-MV
Value-0.50
Score3/3
Weight31.93%
1M Return14.99%
Cash-MV
Value-0.07
Score2/3
Weight13.78%
1M Return7.73%
Net profit / Total profit (%)
Value100.00
Score0/3
Weight-0.41%
1M Return-0.30%
Is CLYM undervalued or overvalued?
  • CLYM scores 5.75/10 on fundamentals and holds a Fair valuation at present. Backed by its -21.77% ROE, 0.00% net margin, -7.93 P/E ratio, 2.10 P/B ratio, and 65.29% earnings growth, these metrics solidify its Netural investment rating.